Phase I/IIDabrafenib and trametinib — solid tumours with BRAF mutation (S)Trametinib — cervical cancer (T), BRAF WT melanoma (C), AML (T), mTNBC (C), myeloma (A), uveal melanoma (C), endometrial cancer (A)GSK1120212 — TNBC and BRAF-WT melanoma (C). This evidence concerns the gene BRAF and plasma cell myeloma.